Revolutionizing Atopic Dermatitis

What do topical PDE4 inhibitors bring to the treatment toolbox? Which patients are likely to get the most use out of them? Robert Sidbury, MD, MPH, answers these questions and more in this video interview.

An abstract presentation at the current Revolutionizing Atopic Dermatitis Conference highlighted using web-based education on AD for nursing students and RNs.

An abstract presented at the Revolutionizing Atopic Dermatitis conference discussed the impact of treatment with dupilumab on quality of life for children aged 6 months to 5 years with atopic dermatitis, as well as their caregivers.

Experts take a closer look at when to watch, and what to watch for in patients on JAK inhibitors.

Expert panelists discussed the pros, cons, and unknowns of the fast-growing roster of new AD treatments in a session at the 4th Annual Revolutionizing Atopic Dermatitis Conference held April 9 to 11, 2022 in Baltimore, Maryland.

Korey Capozza, MPH, the founder and executive director of Global Parents for Eczema Research dives into the importance of the results from their recently released study.

Robert Sidbury, MD, MPH, the division chief of dermatology at Seattle Childrens, expands on his AD overview from the 4th annual Revolutionizing Atopic Dermatitis (RAD) conference is being held from April 9 to 11 in Baltimore, Maryland.

The Revolutionizing Atopic Dermatitis conference begins with presentations focused on new treatments, data, and more in atopic dermatitis.

The first and only atopic dermatitis conference, Revolutionizing Atopic Dermatitis (RAD), will be hosting its third event, in a virtual format.